Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine + Low Dose Cytarabine in Poor Risk MDS
NCT01302106Phase 2Withdrawn
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of clofarabine in myelodysplastic syndrome (MDS), sponsored by Fondazione Italiana Sindromi Mielodisplastiche. Status: withdrawn.
02
Drugs
clofarabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01302106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302106.